Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
ALBUMIN NANOPARTICLES, THE MAKING METHOD, AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/151733
Kind Code:
A1
Abstract:
An albumin nanoparticle comprises a core consisting of at least one diester derivative of β-lapachone and a shell consisting of at least one albumin. Further, a preparation method and use thereof. The albumin nanoparticle has a significantly longer in vivo half-life, markedly reduced toxicity and side effects, and an observably widened therapeutic window, and thus can treat cancer associated with KRAS mutations.

Inventors:
QIAN FENG (CN)
LIU CHUN (CN)
Application Number:
PCT/CN2020/073707
Publication Date:
July 30, 2020
Filing Date:
January 22, 2020
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
NOVAGENESIS THERAPEUTIX HK LTD (CN)
International Classes:
A61K47/42; A61K31/352; A61P35/00
Domestic Patent References:
WO1998014174A11998-04-09
Foreign References:
CN101385857A2009-03-18
Other References:
MA XINPENG; HUANG XIUMEI; MOORE ZACHARY; HUANG GANG; KILGORE JESSICA A; WANG YIGUANG; HAMMER SUNTREA; WILLIAMS NOELLE S; BOOTHMAN : "Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy", JOURNAL OF CONTROLLED RELEASE, vol. 200, 24 December 2014 (2014-12-24), pages 201 - 211, XP029222022, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2014.12.027
XINPENG MA , XIUMEI HUANG , GANG HUANG , LONGSHAN LI , YIGUANG WANG , XIUQUAN LUO , DAVID A. BOOTHMAN , AND JINMING GAO.: ""Prodrug Strategy to Achieve Lyophilizable, High Drug Loading Micelle Formulations Through Diester Derivatives of β-Lapachone"", ADVANCED HEALTHCARE MATERIALS, vol. 3, no. 8, 14 February 2014 (2014-02-14), pages 1210 - 1216, XP055723721, ISSN: 2192-2640, DOI: 10.1002/adhm.201300590
GAURAB CHAKRABARTI , SILVERS MOLLY A., ILCHEVA MARIYA, LIU YULIANG, MOORE ZACHARY R., LUO XIUQUAN, GAO JINMING, ANDERSON GLENDA, L: "Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug,β-lapachone"", SCIENTIFIC REPORTS, vol. 5, no. 1, 17066, 25 November 2015 (2015-11-25), pages 1 - 16, XP055723725, ISSN: 2045-2322, DOI: 10.1038/srep17066
Attorney, Agent or Firm:
WU, FENG & ZHANG (CN)
Download PDF: